Table 1.
Demographic and clinical features of PCA patients and healthy controls.
| Sample#1 |
Sample#2 |
||||||
|---|---|---|---|---|---|---|---|
| PCA | HC | p | PCA | HC | p | p Between patient groups | |
| Number | 8 | 24 | 13 | 20 | |||
| Men/women (% men) | 5/3 (63%) | 14/10 (58%) | 0.84 | 4/9 (31%) | 7/13 (35%) | 0.80 | 0.15 |
| Age at MRI, years | 60.2 ± 4.7 (53–67) | 60.9 ± 6.7 (50–74) | 0.78 | 61.9 ± 6.0 (56–78) | 62.0 ± 2.8 | 0.97 | 0.50 |
| Education, years | 13.6 ± 2.3 (12–17) | 13.0 ± 3.1 (8–18) | 0.63 | 9.5 ± 3.2 (5–13) | 16.0 ± 4.7 | <0.001 | 0.01 |
| Age at onset, years | 55.4 ± 4.8 (49–63) | – | – | 58.5 ± 6.6 (52–77) | – | – | 0.26 |
| Disease duration, years | 4.8 ± 1.6 (3–8) | – | – | 3.4 ± 1.1 (1–5) | – | – | 0.02 |
| CSF, Aβ42* | 552.0 ± 229.0 (414–816) | – | – | 369.4 ± 180.4 (151–607) | – | – | – |
| CSF, T-Tau* | 502.7 ± 174.6 (391–704) | – | – | 339.0 ± 192.6 (80–644) | – | – | – |
| CSF, p-Tau* | 79.4 ± 12.6 (72–94) | – | – | 103.1 ± 100.9 (36–363) | – | – | – |
| CDR | 1.9 ± 0.9 (0.5–3) | – | – | 1.2 ± 0.4 (1–2) | – | – | 0.07 |
| CDR, SB | 10.9 ± 5.8 (0–18) | – | – | 5.4 ± 1.6 (4–8) | – | – | 0.07 |
| ADL | 34.8 ± 25.0 (0–70) | – | – | 5.3 ± 1.1 (3–6) | – | – | NC |
Values denote means ± standard deviations (range or frequencies). CSF normal values Sample#1: Aβ42 > 563.1 ng/L; T-tau < 244.7 ng/L; p-Tau < 83.4 ng/L. CSF normal values Sample#2: Aβ42 > 500 ng/L; T-tau < 450 ng/L; p-Tau < 61 ng/L.
Abbreviations: Aβ42 = amyloid β 42; ADL = activities of daily living; CDR = clinical dementia rating scale; CSF = cerebrospinal fluid; HC = healthy controls; MRI = magnetic resonance imaging; NC = not comparable (different clinical scales); PCA = posterior cortical atrophy; p-tau = phosphorylated protein tau; SB = sum of boxes; T-tau = total tau. * = available for three patients from sample#1 and 9 from sample#2